MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Umerez, Maitane, Gutierrez-Camino, Ángela, Muñoz-Maldonado, Carmen, Martin-Guerrero, Idoia, Garcia-Orad, Africa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376125/
https://www.ncbi.nlm.nih.gov/pubmed/28392709
http://dx.doi.org/10.2147/PGPM.S107047
_version_ 1782519109246779392
author Umerez, Maitane
Gutierrez-Camino, Ángela
Muñoz-Maldonado, Carmen
Martin-Guerrero, Idoia
Garcia-Orad, Africa
author_facet Umerez, Maitane
Gutierrez-Camino, Ángela
Muñoz-Maldonado, Carmen
Martin-Guerrero, Idoia
Garcia-Orad, Africa
author_sort Umerez, Maitane
collection PubMed
description Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes.
format Online
Article
Text
id pubmed-5376125
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53761252017-04-07 MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy Umerez, Maitane Gutierrez-Camino, Ángela Muñoz-Maldonado, Carmen Martin-Guerrero, Idoia Garcia-Orad, Africa Pharmgenomics Pers Med Review Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL). Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes. Dove Medical Press 2017-03-27 /pmc/articles/PMC5376125/ /pubmed/28392709 http://dx.doi.org/10.2147/PGPM.S107047 Text en © 2017 Umerez et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Umerez, Maitane
Gutierrez-Camino, Ángela
Muñoz-Maldonado, Carmen
Martin-Guerrero, Idoia
Garcia-Orad, Africa
MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title_full MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title_fullStr MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title_full_unstemmed MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title_short MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
title_sort mthfr polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376125/
https://www.ncbi.nlm.nih.gov/pubmed/28392709
http://dx.doi.org/10.2147/PGPM.S107047
work_keys_str_mv AT umerezmaitane mthfrpolymorphismsinchildhoodacutelymphoblasticleukemiainfluenceonmethotrexatetherapy
AT gutierrezcaminoangela mthfrpolymorphismsinchildhoodacutelymphoblasticleukemiainfluenceonmethotrexatetherapy
AT munozmaldonadocarmen mthfrpolymorphismsinchildhoodacutelymphoblasticleukemiainfluenceonmethotrexatetherapy
AT martinguerreroidoia mthfrpolymorphismsinchildhoodacutelymphoblasticleukemiainfluenceonmethotrexatetherapy
AT garciaoradafrica mthfrpolymorphismsinchildhoodacutelymphoblasticleukemiainfluenceonmethotrexatetherapy

Ejemplares similares